Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Advances in Neonatal Care : Official Journal of the National Association of Neonatal Nurses|February 15, 2017
Neonatal Resuscitation Program Rolling Refresher: Maintaining Chest Compression Proficiency Through the Use of Simulation-Based EducationJose R Cepeda Brito, Patrick G Hughes, Kimberly S Firestone, et al.
Blood Neoplasia|June 27, 2025
Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: a real-world experienceMalin Hultcrantz, Andriy Derkach, Hani Hassoun, et al.
Blood|May 10, 2024
Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myelomaRoss S Firestone, Nicholas D Socci, Tala Shekarkhand, et al.
Blood Advances|April 15, 2024
Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapiesAnna J Howard, Isabel Concepcion, Alice X Wang, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 26, 2026
Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific AntibodiesIssam S Hamadeh, Maximillian Merz, Andriy Derkach, et al.
JCO Oncology Practice|September 16, 2025
Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up DosesIssam S Hamadeh, Lisa Modelevsky, Amelia Chan, et al.
Blood Advances|April 10, 2024
Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapyIssam S Hamadeh, Tala Shekarkhand, Colin Rueda, et al.
Blood Cancer Journal|April 12, 2026
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myelomaHamza Hashmi, Tara Sebastian, Sridevi Rajeeve, et al.
Blood Advances|May 2, 2025
Outcomes in Frail Patients Receiving BCMA-directed Bispecific Antibodies for Relapsed/Refractory Multiple MyelomaBenjamin O Adegbite, Carlyn Rose Tan, Tala Shekarkhand, et al.
Blood Advances|October 25, 2023
CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myelomaRoss S Firestone, Devin McAvoy, Tala Shekarkhand, et al.
Pageof 5